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A B S T R A C T
Introduction. Psychopathological origins of personally distressing, hypoactive sexual desire disorder (HSDD) in
women are unknown, but are generally attributed to an inhibitory neural regulator, serotonin (5-HT). Flibanserin,
a 5-HT1A agonist and 5-HT2A antagonist, shows promise as a treatment for HSDD.
Aim. To test the hypothesis that female marmoset sexual behavior is enhanced by ﬂibanserin and diminished by
8-OH-DPAT, in order to evaluate the efﬁcacy of serotonergic modulation of female sexual behavior in a pairmate
social setting comparable to humans.
Methods. Sexual and social behavior were examined in eight female marmoset monkeys receiving daily ﬂibanserin
(15 mg/kg), 8-OH-DPAT (0.1 mg/kg), or corresponding vehicle for 15–16 weeks in a counterbalanced, within-
subject design, while housed in long-term, stable male–female pairs.
Main OutcomeMeasures. Marmoset pairmate interactions, including sexual and social behavior, were scored during
weeks 5–6 of daily ﬂibanserin, 8-OH-DPAT or vehicle treatment. 24-hour pharmacokinetic proﬁles of the drugs and
their metabolites, as well as drug-induced acute symptoms of the 5-HT behavioral syndrome were also assessed.
Results. Two-way analysis of variance reveals that ﬂibanserin-treated females attract more male sexual interest
(P = 0.020) and trigger increased grooming (P = 0.001) between partners. In contrast, 8-OH-DPAT-treated females
show increased rejection of male sexual advances (P = 0.024), a tendency for decreased male sexual interest
(P = 0.080), and increased aggression with their male pairmates (P = 0.049).
Conclusions. While 8-OH-DPAT-treated female marmosets display decreased sexual receptivity and increased
aggressive interactions with their male pairmates, ﬂibanserin-treated female marmosets demonstrate increased
afﬁliative behavior with their male pairmates. Such pro-afﬁliation attributes may underlie ﬂibanserin’s effectiveness
in treating HSDD in women. Aubert Y, Gustison ML, Gardner LA, Bohl MA, Lange JR, Allers KA, Sommer
B, Datson NA, and Abbott DH. Flibanserin and 8-OH-DPAT implicate serotonin in association between
female marmoset monkey sexual behavior and changes in pair-bond quality. J Sex Med 2012;9:694–707.
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Introduction
I n an estimated 10% of women [1], marked dis-tress and interpersonal difﬁculty arise from
unwanted, persistent or recurrent low sexual desire
(hypoactive sexual desire disorder, HSDD; Ameri-
canPsychiatric Association’sDiagnostic and Statis-
tical Manual, DSM-IV-TR). Psychopathogenesis
of HSDD is not known, but neurotransmitter dys-
function has been proposed involving the excita-
tory regulators dopamine (DA) andnorepinephrine
(NE), as well as inhibitory serotonin (5-HT) [2,3].
5-HT is a key neurotransmitter involved in female
sexual inhibition [2]. Pharmacological manipula-
tion of 5-HT commonly results in diminished
female sexual satisfaction and activity, particularly
in women prescribed selective serotonin reuptake
inhibitors (SSRIs) for depression [4]. Animal
studies that apply 5-HT receptor subtype speciﬁc
ligands permit mechanistic examination of 5-HT-
mediated effects on sexual behavior. There are
seven known 5-HT receptor families, each with its
own speciﬁc brain distribution, as well as effects on
behavior and physiology [5]. For example, in
rodents, the sexually receptive female lordosis
posture is inhibited by 5-HT1A receptor activation
[6,7] and 5-HT3 receptor antagonism [8], but is
facilitated by 5-HT2A/C receptor activation [9].
Recently, ﬂibanserin (2H-benzimidazol-2-one,
1,3-dihydro-1-[2-[4-[3-(triﬂuoromethyl) phenyl]-
1-piperazinyl]ethyl], an agonist of 5-HT1A and
antagonist of 5-HT2A receptors [11,12], has been
shown to stimulate sexual solicitation and recep-
tivity in female rats [13] and to improve sexual
desire in women with major depression [14].
Women with HSDD report increased satisfying
sexual events, increased desire and decreased
distress following ﬂibanserin treatment [15].
R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin
hydrobromide (8-OH-DPAT), however, a selec-
tive 5-HT1A receptor agonist [16], diminishes
female sexual receptivity in rats [17]. Thus, despite
the shared 5-HT1A agonist activity between ﬂi-
banserin and 8-OH-DPAT, the contrasting effects
of the two drugs on rodent female sexual behavior
provides us with an opportunity to examine
whether such contrasting behavioral outcomes
translate to a nonhuman primate model, the
common marmoset, in a well-established male–
female pairmate social environment.
Female marmoset monkeys present an opportu-
nity to contrast the effects of ﬂibanserin and
8-OH-DPAT in an animal model that readily
translates to humans because marmosets form
stable, long-term, male–female relationships [18]
and display modest amounts of sexual behavior
[19]. Unlike the multiple-mating social structures
of rats and many nonhuman primates, such as
macaques and baboons, marmoset sexual behavior
most commonly occurs within stable male–female
pairs [18,20]. During acceptance or rejection of a
pairmate’s sexual advances, female marmosets can
readily promote, prevent, or terminate sexual
interactions [21], and our recent development of a
standardized behavioral testing paradigm permits
repeatable, quantitative exploration of neurally
active compounds that enhance or diminish female
marmoset sexual behavior [19].
Aims
The aim of the present study was to test the
hypothesis that female marmoset sexual behavior
is enhanced by ﬂibanserin and diminished by
8-OH-DPAT, in order to evaluate the efﬁcacy of
serotonergic modulation of female sexual behavior
in a pairmate social setting comparable to humans.
Methods
Study Animals
This study was conducted in accordance with the
recommendations of the Guide for the Care and
Use of Laboratory Animals and the Animal
Welfare Act and its subsequent amendments. All
animal procedures were reviewed and approved by
the Graduate School Animal Care and Use Com-
mittee of the University of Wisconsin-Madison.
The Wisconsin National Primate Research
Center (WNPRC) is accredited by the Association
for Assessment and Accreditation of Labora-
tory Animal Care as part of the University of
Wisconsin-Madison Graduate School. Sixteen
adult (age 2–5 years) nulliparous captive-born
common marmoset (Callithrix jacchus) females
were pair housed with similarly aged male partners
at the WNPRC for 8–20 months before onset of
this study. Females were housed with the same
male partner for the entire study, as previously
described [22], and were ovariectomized and
primed with either mid-follicular phase estradiol
levels or no hormone [19] before study onset. This
model allows us to provide a repeatable estrogen
replete (estradiol capsules implanted) or estrogen
deﬁcient (empty capsules implanted) hormonal
environment in which sex hormone levels are
stable and reﬂect, respectively, the equivalent of an
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estrogen-dominant, pre-ovulatory stage in the
ovarian cycle or a post-menopausal stage.
Experimental Design
A counterbalanced, crossover study that applied
within-subject comparisons was designed to
examine the effects of chronic (15–16 weeks) daily
(12:00pm–2:00pm) administration of ﬂibanserin
(N = 8; 15 mg/kg, orally (PO) in 1 mL/kg vehicle;
Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach an der Riss, Germany), 8-OH-DPAT
(N = 8; 0.1 mg/kg in 0.4 mL/kg vehicle, injected
subcutaneously (SC); Sigma-Aldrich St. Louis,
MO, USA), or respective vehicles (for ﬂibanserin,
98.5% of 0.5% hydroxycellulose solution and
1.5% of 1% polysorbate 80 solution, 1.0 mL/kg
PO; for 8-OH-DPAT, 0.4 mL saline, SC). The
study focused on two major behavioral outcomes:
(i) sexual and social interactions between pair-
mates; and (ii) acute manifestation of the 5-HT
behavioral syndrome providing quantitative indi-
cation of continued drug efﬁcacy.
As ﬂibanserin was not previously administered
to female marmosets, we performed an initial dose
response study comparing male–female interac-
tions observed after 5–6 weeks of oral dosing of
10 mg/kg (N = 4) or 30 mg/kg (N = 4) ﬂibanserin
to behavior observed during baseline male–female
interactions made prior to these ﬂibanserin treat-
ments. We observed changes in selected behaviors
(Table S1) in our male–female testing paradigm,
described in later discussion, 16–24 hours after
daily ﬂibanserin administration, compared to base-
line. Blood samples assessing pharmacokinetics of
both doses (Figure S1) were obtained after 3–4
weeks. As similar results were obtained from both
doses for behavioral and pharmacokinetic assess-
ments, we decided to employ an intermediate dose
of 15 mg/kg for the main study. The scaled equiva-
lent in humans of 15 mg/kg ﬂibanserin adminis-
tered to marmosets is ~2.4 mg/kg [23] and
approximately similar to ~1.7 mg/kg ﬂibanserin
administered to women in clinical trials (100 mg/
day, assuming 60 kg body weight [24].
8-OH-DPAT has previously been administered
to marmosets in i.p. injections of 0.3 mg/kg,
resulting in pronounced expression of the seroto-
nin behavioral syndrome immediately following
each treatment. 8-OH-DPAT at a dose of
0.3 mg/kg also induces scratching and diarrhea
[25]. To minimize the latter responses and to
remain within a dose range previously used to con-
sistently diminish female sexual behavior in rats
(0.025–1.0 mg/kg, SC or IP [6,17,26], we selected
0.1 mg/kg SC for this study.
Bilateral Ovariectomy
Females were injected intramuscularly (IM) with
ketamine (15 mg/kg), 0.02–0.04 mg/kg atropine
and 0.01 mg/kg buprenorphine, and were main-
tained on isoﬂuorane (2%; 0.6 liter/min oxygen).
Each ovary was isolated through a ventral midline
incision and exteriorized for visualization of the
fallopian tube and ovarian pedicle. Subsequent his-
tological examination conﬁrmed complete ovarian
removal.
Estradiol Replacement
One week before the start of daily treat-
ment, females were implanted SC with silastic
capsules that were either estradiol-ﬁlled (N = 4
per active compound/vehicle) or empty (N = 4
per active compound/vehicle). Plasma estradiol
levels were determined every 2 weeks whenever
capsules were implanted. Treatment with active
compound/vehicle started at (i) either 7 weeks
after ovariectomy or 7 weeks after removal of
capsules; and (ii) 1 week after implantation or
re-implantation of capsules that occurred at 6
weeks after ovariectomy or 6 weeks after removal
of previous capsules, resulting in a constant inter-
treatment interval of 7 weeks. Estradiol status
was maintained throughout treatment for each
female.
Estradiol levels in blood samples that were col-
lected by femoral puncture [22] were determined
using celite column chromatography and a vali-
dated estradiol radioimmunoassay (RIA) for mar-
moset plasma [27]. Assay sensitivity was 4.6 pg/
tube (30.4 pg/mL), and intra- and inter-assay assay
coefﬁcients of variation (CVs), respectively, were
5.0% and 14.0%.
Ovariectomized females implanted with
estradiol-ﬁlled capsules (N = 8) had higher (P <
0.003) circulating estradiol levels (396.0 
30.6 pg/mL) compared to females implanted with
empty capsules (67.5  5.2 pg/mL), and circulat-
ing estradiol values in the former females were
comparable to those previously reported for
female marmosets in the mid-follicular phase of
the ovarian cycle [19]. Estradiol replacement is
thus below the mid-cycle, peri-ovulatory levels
used in some previous studies [28] and thus sup-
ports modest [19] rather than maximal [29] expres-
sion of female marmoset sexual behavior.
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Pharmacokinetic Assessment of Flibanserin and
8-OH-DPAT Administration
Treatment-induced systemic exposure to circulat-
ing levels of ﬂibanserin and two common ﬂi-
banserin metabolites, 1-(3-triﬂuoromethylphenyl)
piperazine (TFMPP) and 6-hydroxy-ﬂibanserin
(BIMA 23 BS), and to 8-OH-DPAT, was assessed
during study weeks 40 to 42 by validated high
performance liquid chromatography coupled to
tandem mass spectrometry (LC-MS/MS). Serial
blood samples were collected at 0.25, 0.5, 1, 3, 6,
and 24 hours after ﬂibanserin or 8-OH-DPAT
administration (N = 4 for each compound).
Behavioral Observation of Sexual and
Social Behavior
In order to stimulate social and sexual interactions
upon reunion [19], females andmaleswere separated
for 90 minutes prior to each of four, 30-minute
behavioral tests at 7:00am–1:00pm (16–24 hours
after daily administration of active compound/
vehicle), 5–6 weeks after treatment onset. This time
window for observations was chosen to assess the
chronic changes induced by ﬂibanserin and 8-OH-
DPAT when circulating levels of drugs were
minimal, thus avoiding potential acute effects driven
by elevated circulating concentrations of the drug
preparations and active metabolites. Potential
behavioral changes are thus consequences of long-
term adaptation to treatment that may involve
changes in gene and protein expression [30].
At the start of the behavioral test, the male was
introduced to the female by remote door opera-
tion, and behavior was manually and digitally
recorded by two observers from behind a one-way
window (Table 1). Behavioral tests were reana-
lyzed in a random fashion from the digitally stored
recordings by two observers blinded with respect
to treatment. The reanalyzed data were compared
with those obtained on the day of the test to
conﬁrm ﬁnal values and to generate behavioral
data not originally scored during live observations
(for aggression and self-grooming). Inter-observer
reliability scores for behavioral data collection
averaged 90.6%, and within-observer reliability
scores averaged 96.1%.
Monitoring of the 5-HT Behavioral Syndrome
Locomotor behaviors indicative of the 5-HTbehav-
ioral syndrome, i.e., “random rapid limb move-
ments” and “wet-dog shakes” [16,25], were
monitored once per week (0.5 hour) at 0–0.5 hour
and at 16–24 hours after administration of active
compound/vehicle treatment, duringweeks 1 to 4 of
treatment (Table 1). Females were placed in a test
cage for the duration of the test (8-OH-DPAT/
vehicle), or returned to their home cage (ﬂibanserin/
vehicle). In addition, sprawling behavior (females
lying down in prone position, monitored during
ﬂibanserin or respective vehicle treatment only), a
possible non-locomotor component of the 5-HT
behavioral syndrome [32], and self-scratching
behavior, a locomotor behavior not speciﬁcally
linked to 5-HT neurotransmission, were scored.
Data Analysis
Observed levels of female proceptive sexual behav-
ior (Table 1) were too infrequent to permit statisti-
cal analysis. Female sexual receptivity was
quantiﬁed by frequency of female acceptance of
male ejaculatory mounts. Female refusal of male
sexual advances was quantiﬁed by frequency of
rejection of male mounts and mount attempts.
Sexual arousal of the male was quantiﬁed by fre-
quency of penile erection. Analyses of all behavior
were performed on transformed frequency data
[square root (1 + x)] to achieve homogeneity of
variance and to increase linearity of data. This
transformation generates positive numbers, per-
mitting appropriate analysis of behavioral fre-
quency data as square root transformation in which
the variance is independent of the mean [33]. Mean
values of the frequencies were analyzed by two-way
anova incorporating repeated measures design,
with Treatment (active compound, vehicle) and
Observations (observation 1–4) as within-subject
factors. Data are presented as backtransformed
mean values (95% conﬁdence intervals). A P value
less than 0.05 was considered signiﬁcant.
Initial analyses of behavioral data were per-
formed using the same mixed design anova with
Estradiol supplementation and Order of treatment
as between-subject factors, and Treatment as
within-subject factor. As Estradiol supplementation
and Order of treatment consistently failed to affect
(P > 0.05) any behavioral variable, both factors were
omitted in the ﬁnal analyses reported here.
Main Outcome Measures
Marmoset pairmate interactions, including sexual
and social behavior,were scored atweeks 5–6of daily
ﬂibanserin, 8-OH-DPAT or vehicle treatment. In
addition, 24-hour pharmacokinetic proﬁles of ﬂi-
banserin, TFMPP, BIMA 23 BS, and 8-OH-DPAT,
aswell as drug-induced acute symptomsof the5-HT
behavioral syndrome, were assessed.
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Results
Systemic Exposure to Flibanserin, Flibanserin
Metabolites, and 8-OH-DPAT during Chronic
Drug Treatment
Maximal plasma concentrations of ﬂibanserin,
TFMPP and BIMA 23 BS (C(max)) of 628 
225 ng/mL (mean  SEM), 46.0  17.0 ng/mL
and 149  38.7 ng/mL, respectively, were reached
at 0.5–1 hour after oral administration, decreasing
rapidly to low levels by 24 hours, providing a cir-
culating half-life for ﬂibanserin of 2.8 hours
(Figure 1). For 8-OH-DPAT, C(max) of 69.7 
19.8 nmol/L was reached by 0.25–0.5 hour after
Table 1 Ethogram and mean  SEM values for behavioral scores during pairmate tests
Behavior
Flibanserin
vehicle Flibanserin
8-OH-DPAT
vehicle 8-OH-DPAT
Proceptive female sexual behavior*
Proceptive tongue flicking 0 0.03  0.06 0 0
Proceptive staring 0 0 0 0
Proceptive freeze posture/Sprawling position 0.16  0.28 0.12  0.14 0.05  0.06 0.06  0.09
Receptive female sexual behaviors*
Acceptance of mounts 0.61  0.58 0.75  0.75 0.23  0.27 0.64  0.57
Rejection of mount attempts and mounts** 0.19  0.28 0.25  0.29 0.62  0.75 1.49  1.50
Receptive freeze posture 0.29  0.28 0.45  0.56 0.23  0.27 0.58  0.55
Receptive tongue flicking 0 0 0 0
Receptive head turning/biting 0.40  0.35 0.35  0.30 0.20  0.23 0.29  0.24
Male sexual behaviors*
Penile erection 0.78  0.65 1.12  0.98 0.89  0.73 1.05  0.46
Mounting 0.61  0.58 0.71  0.69 0.23  0.27 0.64  0.57
Mounting attempts** 0.19  0.28 0.26  0.27 0.63  0.83 1.63  1.59
Intromitting 0.43  0.37 0.48  0.43 0.17  0.20 0.35  0.27
Ejaculating 0.28  0.31 0.26  0.27 0.17  0.20 0.21  0.15
Social odors*
Genital investigation by female 0.03  0.06 0.06  0.08 0.28  0.66 0.08  0.17
Genital investigation by male¶ 1.76  1.54 2.62  1.89 1.12  0.74 0.49  0.39
Scent marking by female 2.54  2.53 3.15  2.67 3.50  3.95 4.36  5.17
Scent marking by male 3.52  4.71 3.39  3.07 5.18  5.23 3.69  2.62
Social interactions*
Grooming by female 1.29  1.57 2.19  2.15 2.77  3.57 1.79  2.60
Grooming by male¶ 2.21  2.02 3.97  3.27 1.09  0.57 0.76  0.47
Total allogrooming¶ 3.94  2.22 6.91  3.20 4.07  3.74 2.71  2.69
Aggression by female 0.94  1.17 0.78  1.07 0.92  1.03 1.66  1.76
Aggression by male 0.06  0.08 0.17  0.23 0.18  0.18 0.53  0.62
Total aggression** 0.99  1.21 0.91  1.27 1.09  1.14 2.23  1.98
Contact within arm-length 5.54  1.23 5.42  1.04 7.71  2.04 6.27  1.75
Direct body contact/huddling 8.69  1.72 10.37  2.60 9.42  2.84 9.77  2.48
Total contact 14.30  2.07 15.87  3.07 17.62  1.55 16.19  3.30
Initiating contact by female 11.14  5.67 10.99  3.41 20.13  8.08 16.99  7.84
Breaking contact by female 15.60  5.99 15.03  7.71 21.09  6.46 14.27  7.20
Following by female 1.60  1.66 1.67  1.39 3.00  2.52 2.60  2.33
Avoiding contact by female 1.69  1.15 1.53  1.22 1.60  1.00 1.15  0.61
Self-directed behavior by female*
Self-grooming¶ 2.75  1.86 3.96  1.95 1.00  0.55 1.89  1.25
Genital inspection/Genital self-grooming¶ 1.87  1.58 4.18  2.95 0.45  0.43 0.33  0.23
Scratching 12.74  8.73 11.50  4.94 8.44  5.09 10.95  3.56
Locomotion and movement by female*
Mobile in locomotion 2.50  0.74 1.93  0.53 3.07  1.15 2.39  1.03
Mobile while stationary 4.45  1.55 5.33  1.64 4.06  1.95 4.14  1.41
Mobile total 6.97  2.14 7.29  1.92 7.25  2.47 6.67  1.63
Immobile, incl. sprawling position 22.72  2.09 22.47  1.77 22.33  2.59 23.14  1.59
Acute behavioral changes†
Scratching* 7.32  2.40 5.23  2.32 1.50  0.90 5.56  4.49
Random rapid limb movements‡** 0 0 0 6.89  4.32
“Wet-dog” shakes‡** 0.24  0.16 0.11  0.18 0 17.44  11.90
Latency to sprawling position§¶ 19.47  4.19 14.58  4.71 Not scored Not scored
A zero value indicates complete absence of behavior. Bold numbers indicate significant changes compared to vehicle treatment. 8-OH-DPAT, R-(+)-8-hydroxy-2-
(di-n-propylamino)-tetralin
*Adapted from Stevenson and Poole [21]. Behavior was recorded at 16–24 hours after daily drug/vehicle administration during weeks 5–6 of daily treatment
†Behavior was recorded at 0–0.5 hours after drug/vehicle administration during weeks 1–4 of daily treatment
‡Behavior indicative of the 5-HT behavioral syndrome. Elliott et al. [25]
§Behavior resembling the rodent flat-body posture. Tricklebank et al. [31]
¶Significantly altered by flibanserin administration (P < 0.05)
**Significantly altered by 8-OH-DPAT administration (P < 0.05)
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SC injection, and values dropped rapidly to
3.4  2.6 nmol/L after 3 hours, providing a circu-
lating half-life of 8-OH-DPAT of 0.6 hour
(Figure 1). No cumulative effects of chronic
8-OH-DPAT and ﬂibanserin administration were
apparent. The results conﬁrm a substantial sys-
temic exposure to ﬂibanserin, BIMA 23 BS,
TFMPP and 8-OH-DPAT during observations
for 5-HT behavioral syndrome, but not during
pairmate observations. Thus, treatment-induced
changes during pairmate observations are most
likely attributable to the long-term consequences
of ﬂibanserin and 8-OH-DPAT exposure, and not
to acute effects elicited by elevated circulating
levels of active drug.
Chronic Effects of 8-OH-DPAT and Flibanserin on
Sexual, Social and Self-Directed Behavior
Five to six weeks of daily oral administration of
ﬂibanserin to female marmosets noticeably
increased female genital area self-grooming
(F(1,7) = 31.28, P = 0.001; Figure 2A) and male
pairmate snifﬁng/licking of their female’s genital
area (F(1,7) = 8.91, P = 0.020; Figure 2B). No
other sexually related behavior was altered by ﬂi-
banserin (Table 1). In contrast, 5–6 weeks of daily
SC administration of 0.1 mg/kg 8-OH-DPAT
strikingly increased female rejection of male pair-
mate mount attempts and mounts compared to
corresponding vehicle (F(1,7) = 8.24, P = 0.024;
Figure 3). 8-OH-DPAT-induced female rejection
Figure 1 24-hour pharmacokinetic
profiles of flibanserin and 8-OH-
DPAT in female marmoset monkeys.
Pairmate observations were per-
formed at 16–24 hours after adminis-
tration, when exposure to circulating
drug concentrations was low or
absent, while observation of the 5-HT
behavioral syndrome was performed
at 0–0.5 hour after administration,
when circulating drug concentrations
were high. 8-OH-DPAT, R-(+)-8-
hydroxy-2-(di-n-propylamino)-tetralin;
5-HT, serotonin.
Figure 2 Investigation of female genital area. Frequencies (backtransformed mean) of (A) female genital area self-
grooming and (B) male inspection of female genital area per 30 minutes during 5–6 weeks following the onset of flibanserin,
flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT vehicle administration. *** P = 0.001 vs. flibanserin vehicle (F(1,7) = 31.3),
* P = 0.020 vs. flibanserin vehicle (F(1,7) = 8.9), † P = 0.080 vs. 8-OH-DPAT vehicle (F(1,7) = 4.2). Each symbol indicates
the same individual female marmoset receiving estradiol (solid symbols) or no estradiol (open symbols). 8-OH-DPAT,
R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
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of male sexual advances also increased male
attempts to mount their female pairmate
(F(1,7) = 6.93, P = 0.034). The male pairmates of
8-OH-DPAT treated females also tended to sniff/
lick their female pairmate’s genital area less
(F(1,7) = 4.20, P = 0.080; Figure 2B), and
decreased male genital snifﬁng was correlated with
female rejection of male mount attempts and
mounts (r = -0.747, P = 0.033). No other sexually
related behavior was altered (Table 1).
Such opposing effects of ﬂibanserin and 8-OH-
DPAT were also observed in social interactions
between male and female pairmates. Flibanserin
increased allogrooming between pairmates
(F(1,7) = 34.25, P = 0.001; Figure 4A), mostly
male grooming of their female pairmates
(F(1,7) = 6.25, P = 0.041). 8-OH-DPAT, in con-
trast, tended to diminish allogrooming between
males and females (F(1,7) = 4.23, P = 0.079;
Figure 4A), including a trend toward diminished
male grooming of female pairmates
(F(1,7) = 4.92, P = 0.062). Frequency of aggres-
sive interactions between the pairmates was
increased by 8-OH-DPAT (F(1,7) = 5.65,
P = 0.049; Figure 4B), but not by ﬂibanserin
(F(1,7) = 0.09, P = 0.778). This 8-OH-DPAT
induced increase in aggression positively corre-
lated with increased female rejection of male
mount attempts and mounts (r = 0.941,
P < 0.001), and correlated negatively with male
genital snifﬁng (r = -0.834, P = 0.010). No other
changes in social behavior were induced by ﬂi-
banserin or 8-OH-DPAT (Table 1).
Female self-grooming behavior was increased
by ﬂibanserin (F(1,7) = 7.13, P = 0.032), but not by
8-OH-DPAT (F(1,7) = 3.02, P = 0.126). There
Figure 3 Female sexual rejection. Frequency (backtrans-
formed mean) of female rejection of male mounts and
mount attempts per 30 minutes during 5–6 weeks of fli-
banserin, flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT
vehicle administration. * P = 0.024 vs. 8-OH-DPAT vehicle
(F(1,7) = 8.2). Each symbol indicates the same individual
female marmoset receiving estradiol (solid symbols) or no
estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-
(di-n-propylamino)-tetralin.
Figure 4 Pairmate allogrooming and aggression. Frequencies (backtransformed mean) of (A) allogrooming and (B)
aggressive interactions between pairmates per 30 minutes during 5–6 weeks of flibanserin, flibanserin vehicle, 8-OH-DPAT,
or 8-OH-DPAT vehicle administration. *** P = 0.001 vs. flibanserin vehicle (F(1,7) = 34.2), † P = 0.079 vs. 8-OH-DPAT vehicle
(F(1,7) = 4.2), * P = 0.049 vs. 8-OH-DPAT vehicle (F(1,7) = 5.6). Each symbol indicates the same individual female marmoset
receiving estradiol (solid symbols) or no estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
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were no other behavioral effects of either drug on
self-directed behaviors (Table 1). Estradiol supple-
mentation, in both 8-OH-DPAT and ﬂibanserin
groups, was without effect on pairmate behavior.
Effects of Flibanserin and 8-OH-DPAT on Acute
Induction of the 5-HT Behavioral Syndrome
During pairmate observations to assess sexual and
social behavior (7:00am–1:00pm, 16–24 hours fol-
lowing daily drug administration), neither 8-OH-
DPAT nor ﬂibanserin resulted in females display-
ing symptoms of the potentially disruptive 5-HT
behavioral syndrome.
Directly (0–0.5 hour) following administration,
however, ﬂibanserin shortened the latency to the
ﬁrst occurrence of sprawling or prone behavior
(Figure 5, F(1,7) = 11.90, P = 0.011), without
affecting the frequency of this behavior
(F(1,7) = 0.44, P = 0.528). Furthermore, in con-
trast to 8-OH-DPAT, ﬂibanserin ﬁrst increased
(weeks 1–3) female scratching behavior 0–0.5 hour
after administration (F(3,21) = 5.64, P = 0.005),
and then diminished scratching behavior over
the remaining weeks of ﬂibanserin treatment
compared to corresponding vehicle treatment
(Treatment ¥ Week interaction [F(3,21) = 7.21,
P = 0.002]).
In contrast to ﬂibanserin, 8-OH-DPAT consis-
tently induced locomotor components of an acute,
transient 5-HT behavioral syndrome in female
marmosets 0–0.5 hour after administration, which
persisted over the entire time course (15–16 weeks)
of chronic treatment. In 8-OH-DPAT-treated
female marmosets, the acute 5-HT behavioral syn-
drome involved displays of “random rapid limb
movements” (Figure 6A, F(1,7) = 16.67, P = 0.005)
and “wet-dog shakes” (Figure 6B, F(1,7) = 19.81,
P = 0.003). In addition, frequency of scratching
behavior tended to be elevated 0–0.5 hour after
8-OH-DPAT administration (Figure 6C, F(1,7) =
5.46, P = 0.052), but therewas aTreatment ¥ Week
interaction (F(1,7) = 15.39, P < 0.001). Post hoc
analysis indicated that female marmosets demon-
Figure 5 Sprawling behavior. Latency (minutes; back-
transformed mean) to the first occurrence of sprawling
behavior by female marmosets during pairmate observation
after 5–6 weeks of flibanserin or flibanserin vehicle.
* P = 0.011 vs. flibanserin vehicle (F(1,7) = 11.90). Each
symbol indicates the same individual female marmoset
receiving estradiol (solid symbols) or no estradiol (open
symbols).
Figure 6 Acute induction of the 5-HT behavioral syndrome. Frequency (backtransformed mean) of female (A) “rapid,
random limb movements” behavior (B) “wet dog shake” behavior, and (C) scratching behavior per 30 minutes during 5–6
weeks of flibanserin, flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT vehicle and following 0–0.5 hours of treatment admin-
istration. ** P < 0.01 vs. 8-OH-DPAT vehicle (“rapid, random limb movements”: F(1,7) = 16.7; “wet dog shakes”:
F(1,7) = 19.8), † P = 0.052 vs. 8-OH-DPAT vehicle (F(1,7) = 5.46). Each symbol indicates the same individual female
marmoset receiving estradiol (solid symbols) or no estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-
propylamino)-tetralin.
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strated an acute onset of scratching behavior during
the ﬁrst week of 8-OH-DPAT treatment (week 1),
but not during subsequent weeks. As found with
5-HTbehavioral syndromebehaviors, therewas no
effect of 8-OH-DPAT treatment on scratching
behavior at 16–24 hours following drug adminis-
tration (F(1,7) = 1.75, P = 0.227) when pairmate
behavioral observations were conducted.
Discussion
Despite the prevalence of HSDD among women
[1,3], its psychopathogenesis is unknown. Pharma-
cological manipulation of 5-HT, however, com-
monly induces an HSDD-like condition,
especially in women chronically treated with
SSRIs for depression [4], likely involving 5-HT1A
receptors [34]. Flibanserin, a 5-HT1A post-
synaptic receptor agonist and 5-HT2A antagonist,
presents a pharmacological opportunity to amelio-
rate psychosexual distress in women. Flibanserin
improves sexual desire in women with major
depression [14], and in women with HSDD it has
been demonstrated to increase satisfying sexual
events, sexual desire, and decreases distress [15].
Female marmosets, already established as a
mechanistic model for neural regulation of female
sexual behavior [19,28], form stable, long-term,
male–female relationships [18] that allow for the
examination of the pharmacological efﬁcacy of ﬂi-
banserin with regard to female sexual behavior.
Chronic administration of ﬂibanserin to female
marmoset pairmates stimulates male inspection of
female genital area and increases female genital
self-grooming. Female sexual behavior, however, is
otherwise unaltered, possibly because we employ
well-established male–female pairs without a
history of infrequent-to-absent sexual behavior.
Enhancement of proceptive and receptive aspects
of female marmoset sexual behavior can be quan-
tiﬁed using our behavioral testing paradigm, as
previously shown following administration of
gonadotropin releasing-hormone II and respective
analogues [19]. In contrast, 8-OH-DPAT (a
5-HT1A pre- and postsynaptic receptor agonist)
administered to female marmoset pairmates tends
to diminish male inspection of female genitalia and
increases female rejection of male-initiated sexual
advances, thus diminishing female sexual receptiv-
ity toward their long-standing male pairmate. The
comparability of behavioral responses in both
estrogen and “no hormone replaced” ovariecto-
mized female marmosets used in this study sug-
gests applicability of our results to both pre- and
post-menopausal conditions in women, as found in
a previous marmoset study [19].
The differential effects of ﬂibanserin and
8-OH-DPAT on female marmoset sexual behavior
resemble ﬁndings in female rats. Female rats given
ﬂibanserin increase expression of proceptive and
receptive sexual behavior and receive increased
genital snifﬁng by the male pairmate [13], whereas
female rats given 8-OH-DPAT exhibit diminished
female sexual receptivity [17]. These contrasting
effects of ﬂibanserin and 8-OH-DPAT on marmo-
set and rodent behavior are surprising since both
compounds are described as 5-HT1A agonists.
However, while both ﬂibanserin and 8-OH-DPAT
activate postsynaptic 5-HT1A receptors, ﬂibanserin
is functional only as a postsynaptic receptor
agonist [15], whereas 8-OH-DPAT activates both
pre- and postsynaptic 5-HT1A receptors. This dif-
ference in biological action results in fundamental
differences in pharmacology and the abilities of
ﬂibanserin and 8-OH-DPAT to induce functional
changes in a brain region-speciﬁc manner. For
example, ﬂibanserin inhibits forskolin-stimulated
cAMP formation in the cortex, while 8-OH-
DPAT does not affect cortical cAMP accumulation
[10]. Flibanserin decreases neuronal ﬁring rate in
the rat cortex regardless of whether the presynap-
tic receptor-containing dorsal raphé nucleus is
intact, while the effects of 8-OH-DPAT are
dependent upon intact raphé serotonergic neurons
[11]. Taken together, ﬂibanserin and 8-OH-DPAT
display a different regional selectivity, and they
differentially affect neuronal function in 5-HT
projection sites.
These functional differences are particularly
evident in pyramidal neurons in the prefrontal
cortex, a key site for ﬂibanserin’s mode of action
in affecting female sexual behavior, as these
neurons are an important part of regulatory net-
works that coordinate the release of 5-HT, DA and
NE in a brain region-speciﬁc manner [15]. Addi-
tional 5-HT2A antagonist effects of ﬂibanserin,
which 8-OH-DPAT lacks, have been shown to
enhance 5-HT1A agonist effects on pyramidal
neurons of the prefrontal cortex, thus creating a
biochemical environment in ﬂibanserin-exposed
prefrontal cortex that is clearly different from
8-OH-DPAT exposure. 8-OH-DPAT is thus not
likely to directly affect cortical neurocircuitries
[10], but will suppress female sexual behavior
by acting on 5-HT1A receptors in postsynaptic
hypothalamic areas, such as the ventromedial
hypothalamus [35] and medial preoptic area [36],
or in presynaptic raphé nuclei [37]. Thus, ﬂi-
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banserin’s effects on female sexual behavior are
likely mediated by altering cortical neurocircuit-
ries, while 8-OH-DPAT likely inhibits female
sexual behavior by activation of hypothalamic or
midbrain 5-HT1A receptor populations. The
inhibitory effects of 8-OH-DPAT occur immedi-
ately and do not require chronic administration in
rats [6]. Chronic administration seems not to lead
to either tolerance or sensitization of sexual
behavior, at least in male rats [38]. Flibanserin, in
contrast, might regulate female sexual behavior by
affecting pyramidal neurons in the prefrontal
cortex and establishing a new monoamine neu-
rotransmitter balance in a brain region-speciﬁc
manner [15]. Chronic elevations in prefrontal
cortex levels of DA and NE in rats are reported
after 21 days of repeated ﬂibanserin administra-
tion, consistent with the duration needed for ﬂi-
banserin to facilitate female sexual behavior in rats
[13].
Flibanserin’s enhancement of interest in treated
female marmosets’ genitals is reminiscent of its
effects when administered twice daily to female
rats (45 mg/kg, PO) for 2–3 weeks. Flibanserin-
treated female rats attract increased male inspec-
tion of their genital area [13]. In both rats and
marmosets, female genital odor is important for
activation of male sexual arousal [rat: [39]; marmo-
set: [40]], particularly, female genital odor from
the peri-ovulatory period when female sexual pro-
ceptivity and receptivity are maximal [rat: [41];
marmoset: [42]]. 5-HT regulates likely mediators
of genital olfactory attractiveness, such as oxyto-
cinergic (OT) and vasopressinergic (AVP) neurons
[43] that innervate female external genitalia, pos-
sibly in conjunction with the central DA neu-
rotransmitter system [44]. Neuro-regulated
changes in vaginal odor may also be a consequence
of 5-HT-mediated alterations in genital vasodila-
tation [44] or salt-water regulation [45]. Increased
female interest in genital self-grooming and self-
grooming, in general, could involve 5-HT medi-
ated changes in OT, as central administration of
OT (and AVP) to female rats increases self-
grooming, particularly of the genital area [46].
Perhaps the most intriguing ﬁnding of this mar-
moset study, the opposing effects of ﬂibanserin and
8-OH-DPAT on the quality of male–female pair
interactions, raises the possibility that female sexu-
ality is strongly inﬂuenced by the perceived quality
of the relationship with their partner (e.g., [3,47]).
Social attachment and maintenance of proximity,
allogrooming and pair-bonding, function to facili-
tate reproduction [48] and sexual behavior may
contribute toward maintenance of a close male–
female relationship [49]. In marmosets, afﬁliative
behavior between females and males co-occurs
with sexual behavior, while aggressive behavior
between pairmates impedes sexual interaction
[50,51]. Thus, the aggression-inducing effect of
8-OH-DPAT and the afﬁliation-enhancing effect
of ﬂibanserin may create relationship environ-
ments that either diminish or facilitate sexual
interactions between marmoset pairmates, respec-
tively, likely mediated by neurotransmitter systems
implicated in the regulation of social behavior,
such as 5-HT [52], DA [53], AVP and OT [54,55].
Flibanserin selectively activates postsynaptic
5-HT1A receptors while antagonizing 5-HT2A
receptors [11]. Gerretsen et al. [56] recently
reported a negative association between the desire
for social relationships in humans and 5-HT2A
binding in the prefrontal cortex. Furthermore, ﬂi-
banserin’s distinct receptor binding proﬁle induces
long-lasting increases in basal DA in the prefrontal
cortex, while not changing basal levels in other
tested brain areas, including the hypothalamus
and nucleus accumbens [57,58]. If replicated in
ﬂibanserin-treated female marmosets, such
increases in prefrontal cortex DA would be
expected to enhance prefrontal cortex-guided
attention to male behavioral cues and to more
readily elicit female responses based on previous
experience [58]. Improved efﬁciency of DA-
mediated neural processing is proposed as one
aspect of therapeutic efﬁcacy for a variety of drugs
that improve disorders of PFC dysfunction, possi-
bly including HSDD [59,60].
Beyond neurobiological factors that inﬂuence
sexual function, several studies, including the
National and Social Life Survey [61], point out
that sexual behavior in women is closely linked to
psychosocial factors and quality of their relation-
ship with a partner [47]. The complex interplay of
these factors with hormonal and neural environ-
ments is a challenge for any animal model of
female sexual function. The translation of rodent
ﬁndings to humans, for example, is difﬁcult in light
of their strict circadian hormonal control of female
sexual function [62]. Studies in non-primate
mammals are thus not likely able to capture the
multifactorial environment in which sexual behav-
ior is expressed in nonhuman primates and
humans [63]. In contrast, our observations in the
marmoset monkey emulate the human situation
more closely and highlight the importance of pair-
bond quality in female sexual behavior. Our ﬁnd-
ings are likely based within an important set of
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marmoset-typical characteristics, including well-
developed social behavior, long-term female–male
pairings and a degree of emancipation of female
sexual behavior from strict hormonal control [28]
that permit a signiﬁcant inﬂuence of the social
environment on the shaping of sexual behavior.
The strong and consistent, but transient, expres-
sion of a 5-HT behavioral syndrome induced in
female marmosets by 8-OH-DPAT administration
is likely mediated by activation of postsynaptic
5-HT1A receptors [64,65]. Flibanserin, in contrast,
does not elicit shaking or rapid limb movements
despite its postsynaptic 5-HT1A agonist character-
istic. This may be due to ﬂibanserin’s 5-HT2A
antagonist property, as 5-HT1A and 5-HT2A recep-
tors are functionally linked and show reciprocal
modulation [66]. Indeed, pretreatment with
5-HT2A antagonists reduces 8-OH-DPAT-induced
5-HT behavioral syndrome in rats [31]. It is pos-
sible that ﬂibanserin increases the expression of
brain-derived neurotrophic factor (BDNF) in the
cerebral cortex and hippocampus, which, in rats,
diminishes the 5-HTbehavioral syndrome induced
by 8-OH-DPAT [67]. A shortened latency to
sprawl induced by ﬂibanserin may be equivalent to
the ﬂat-body posture component of the 5-HT
behavioral syndrome [32]. Sprawling, however, is
also commonly observed when marmosets solicit
allogrooming from a partner [21]. Thus, a short-
ened latency to sprawling behavior may indicate
another pro-social effect of ﬂibanserin rather than a
ﬂibanserin-induced component of the 5-HT
behavioral syndrome. Neither sprawling in ﬂi-
banserin treated females, nor the 5-HT behavioral
syndrome displayed by 8-OH-DPAT treated
females, are likely related to 5-HT toxicity (or
5-HT syndrome) described in humans, a poten-
tially life-threatening condition induced by excess
5-HT [68]. 5-HT toxicity can result from combi-
nations of antidepressant treatments, such as
monoamine oxidase inhibitors (MAOIs) andSSRIs,
causing clonus (involuntarymuscle contraction and
relaxation) and hyperthermia [68] apparently due
to 5-HT2 receptor-mediated effects [69]. Activa-
tion of 5-HT1A receptors, in contrast, commonly
leads to hypothermia in rodents and humans
[70,71]. Flibanserin, a 5-HT1A agonist and 5-HT2A
receptor antagonist, and 8-OH-DPAT, a 5-HT1A
agonist, are thus both unlikely to cause hyperther-
mic responses. Furthermore, both ﬂibanserin and
8-OH-DPAT administered to rodents selectively
decrease 5-HT synthesis in several brain regions
[72], further indicating the unlikelihood of either
contributing to 5-HT toxicity.
Similar to a previous observation indicating that
low-level estradiol supplementation is not required
for the efﬁcacy of gonadotropin-releasing hormone
II to stimulate sexual behavior in ovariectomized
female marmosets [19], our present study, applying
the same design in regard to estradiol replacement,
demonstrates that behavioral changes due to
chronic ﬂibanserin and 8-OH-DPAT treatments
are independent of estradiol status. This ﬁnding
might be somewhat surprising in light of well-
documented interactions of estrogens with the
central serotonin system [73] and contrast with a
previous study conducted by Kendrick and Dixson
[29]. Kendrick and Dixson [29], however, applied
high levels of estradiol supplementation equivalent
to pre-ovulatory peak levels (~940 pg/mL). The
much lower circulating estradiol levels in our study
(average with estradiol supplementation: 396 pg/
mL), chosen to facilitate a low tomodest baseline of
sexual behavior, may be responsible for the lack of
obvious estradiol-induced behavioral changes in
the present study.
Conclusions
Our ﬁndings are the ﬁrst to demonstrate differen-
tial and potentially bi-directional regulation of
female sexual behavior (diminished versus
unchanged) and social behavior (diminished
versus enhanced) in a nonhuman primate through
prolonged serotonergic modulation, supporting
the central 5-HT system as a promising target for
pharmacotherapy of sexual dysfunction in women.
Our model applies species-appropriate settings in
which female partners can control sexual and
social interactions. We show that female marmo-
set sexual behavior is suppressed by selective
chronic stimulation of 5-HT1A receptors by
8-OH-DPAT. In contrast, through its distinctively
different 5-HT receptor binding proﬁle, and
potential additional abilities to enhance DA levels
(and possibly other neurotransmitters) in a brain-
region speciﬁc manner [57,58], ﬂibanserin
increases pro-social interactions in male and
female marmoset pairmates without obvious
enhancement of female sexual behavior. While
these ﬁndings suggest that ﬂibanserin’s effects
may not translate from female marmosets to
women in every respect, they do show that ﬂi-
banserin enhances species-speciﬁc, intimate
aspects of partner interactions. These are manifest
by increased intimate afﬁliative engagement
between marmoset pairmates and improved sexual
relationships between women and their partners
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[14]. Thus, the putative beneﬁcial effect of ﬂi-
banserin on sexual well-being in women, other-
wise distressed about low sexual desire, may arise
from its ability to positively inﬂuence the quality
of relationship with long-term partners. Our
observations of female marmosets may therefore
suggest the need to integrate mechanistic, neuro-
chemical explanations of female sexual behavior
with holistic views of health psychology, including
emotional and relational aspects of female sexual-
ity, in order to successfully contribute novel thera-
peutic approaches to female sexual well-being.
Acknowledgments
We thank the veterinary staff and animal care staff at the
WNPRC including Dr. Kevin Brunner, Vicky Carter,
Megan Sosa and Marilina Vazquez for assistance with
animal care, and Amber Edwards, Kristie Barnick-
Snyder, Nicole Diol, Alison Parker-Cole and Brian
Pisula for technical assistance with marmoset observa-
tion and blood sample collection. Fritz Wegner and
Dan Wittwer provided excellent technical assistance
with hormone assays. We gratefully acknowledge
Laurie Poast for graphic design.
This study was supported by Boehringer Ingelheim
(to D.H.A.) and was conducted in part at a facility con-
structed with support from Research Facilities Improve-
ment Program grant numbers RR15459-01 and
RR020141-01.
Corresponding Author: Yves Aubert, MS, Medical
Pharmacology, LACDR, Leiden University Medical
Centre, Einsteinweg 55, 2333 CC Leiden, the Nether-
lands. Tel: +31715276301; Fax: +31715274715; E-mail:
auberty@lacdr.leidenuniv.nl
Conﬂict of Interest: Dr. Abbott reports having received a
grant from Boehringer Ingelheim that supported the
work of Yves Aubert, Morgan Gustison, Lindsey
Gardner, Michael Bohl, and Jason Lange. Dr. Allers and
Dr. Sommer are employed by Boehringer Ingelheim.
Dr. Datson currently holds a grant from Boehringer
Ingelheim to perform molecular follow up studies of the
work described here.
Statement of Authorship
Category 1
(a) Conception and Design
David H. Abbott; Bernd Sommer; Yves Aubert
(b) Acquisition of Data
Yves Aubert; Morgan L. Gustison; Lindsey A.
Gardner; Michael A. Bohl; Jason R. Lange
(c) Analysis and Interpretation of Data
Yves Aubert; David H. Abbott; Kelly A. Allers;
Nicole A. Datson
Category 2
(a) Drafting the Article
Yves Aubert
(b) Revising It for Intellectual Content
David H. Abbott; Nicole A. Datson; Kelly A. Allers;
Bernd Sommer; Morgan L. Gustison; Lindsey A.
Gardner; Michael A. Bohl; Jason R. Lange
Category 3
(a) Final Approval of the Completed Article
Yves Aubert; Morgan L. Gustison; Lindsey A.
Gardner; Michael A. Bohl; Jason R. Lange; Kelly A.
Allers; Bernd Sommer; Nicole A. Datson; David H.
Abbott
References
1 Clayton AH. The pathophysiology of hypoactive sexual desire
disorder in women. Int J Gynaecol Obstet 2010;110:7–11.
2 Pfaus JG. Pathways of sexual desire. J Sex Med 2009;6:1506–
33.
3 Clayton AH, Hamilton DV. Female sexual dysfunction. Psy-
chiatr Clin North Am 2010;33:323–38.
4 Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual
function: A critical review. J Clin Psychopharmacol 1999;19:
67–85.
5 Barnes NM, Sharp T. A review of central 5-HT receptors and
their functions. Neuropharmacology 1999;38:1083–152.
6 Ahlenius S, Fernandez-Guasti A, Hjorth S, Larsson K. Sup-
pression of lordosis behavior by the putative 5-HT receptor
agonist 8-OH-DPAT in the rat. Eur J Pharmacol 1986;124:
361–3.
7 Uphouse L, Caldarola-Pastuszka M, Montanez S. Intra-
cerebral actions of the 5-HT1A agonists, 8-OH-DPAT and
buspirone and of the 5-HT1A partial agonist/antagonist,
NAN-190, on female sexual behavior. Neuropharmacology
1992;31:969–81.
8 Maswood N, Caldarola-Pastuszka M, Uphouse L. 5-HT3
receptors in the ventromedial nucleus of the hypothalamus and
female sexual behavior. Brain Res 1997;769:13–20.
9 Mendelson SD, Gorzalka BB. A facilitatory role for serotonin
in the sexual behavior of the female rat. Pharmacol Biochem
Behav 1985;22:1025–33.
10 Borsini F, Giraldo E, Monferini E, Antonini G, Parenti M,
Bietti G, Donetti A. BIMT 17, a 5-HT2A receptor antagonist
and 5-HT1A receptor full agonist in rat cerebral cortex.
Naunyn Schmiedebergs Arch Pharmacol 1995;352:276–282.
11 Borsini F, Ceci A, Bietti G, Conetti A. BIMT 17, a 5-HT1A
receptor agonist/5-HT2A receptor antagonist, directly acti-
vates postsynaptic 5-HT inhibitory responses in the rat cere-
bral cortex. Naunyn Schmiedebergs Arch Pharmacol 1995b;
352:283–90.
12 Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier
S. Pharmacology of ﬂibanserin. CNS Drug Rev 2002;8:117–
42.
13 Gelez H, Allers K, Sommer B, Giuliano F. Chronic Fli-
banserin treatment increases solicitations in the female rat. J
Sex Med 2010;7(suppl 3):118.
14 Kennedy S. Flibanserin: Initial evidence of efﬁcacy on sexual
dysfunction, in patients with major depressive disorder. J Sex
Med 2010;7:3449–59.
15 Stahl SM, Sommer B, Allers KA. Multifunctional pharmacol-
ogy of ﬂibanserin: Possible mechanism of therapeutic action
in hypoactive sexual desire disorder. J Sex Med 2011;8:15–
27.
Flibanserin Alters Primate Pairmate Relations 705
J Sex Med 2012;9:694–707
16 Arvidsson LE, Hacksell U, Nilsson JL, Hjorth S, Carlsson
A, Lindberg P, Sanchez D, Wikstrom H. 8-Hydroxy-2-
(di-n-propylamino)tetralin, a new centrally acting 5-
hydroxytryptamine receptor agonist. J Med Chem 1981;24:
921–3.
17 Uphouse L, Montanez S, Richards-Hill R, Caldarola-
Pastuszka M, Droge M. Effects of the 5-HT1A agonist, 8-OH-
DPAT, on sexual behaviors of the proestrous rat. Pharmacol
Biochem Behav 1991;39:635–40.
18 Abbott DH, Barnett DK, Colman RJ, Yamamoto ME,
Schultz-Darken NJ. Aspects of common marmoset basic
biology and life history important for biomedical research.
Comp Med 2003;53:339–50.
19 Barnett DK, Bunnell TM, Millar RP, Abbott DH.
Gonadotropin-releasing hormone II stimulates female sexual
behavior in marmoset monkeys. Endocrinology 2006;147:615–
23.
20 Evans S, Poole TB. Long-term changes and maintenance of
the pair-bond in common marmosets, Callithrix jacchus jacchus.
Folia Primatol 1984;42:33–41.
21 Stevenson MF, Poole TB. An ethogram of the common mar-
moset (Calithrix jacchus jacchus): General behavioural reper-
toire. Anim Behav 1976;24:428–51.
22 Hearn JP. Restraining device for small monkeys. Lab Anim
1977;11:261–2.
23 Sharma V, McNeill JH. To scale or not to scale: The principles
of dose extrapolation. Br J Pharmacol 2009;157:907–21.
24 Jolly E, Clayton AH, Thorp J, Kimura T, Sand M, Pyke R.
Efﬁcacy of ﬂibanserin 100 mg qhs as a potential treatment for
hypoactive sexual desire disorder in North American pre-
menopausal women. J Sex Med 2009;6(suppl 5):465.
25 Elliott PJ, Walsh DM, Close SP, Higgins GA, Hayes AG.
Behavioural effects of serotonin agonists and antagonists in
the rat and marmoset. Neuropharmacology 1990;29:949–
56.
26 Johansson CE, Meyerson BJ. The effects of long-term
treatment with 8-OH-DPAT on the lordosis response and
hypothermia in female rats. Eur J Pharmacol 1991;196:143–7.
27 Saltzman W, Schultz-Darken NJ, Wegner FH, Wittwer DJ,
Abbott DH. Suppression of cortisol levels in subordinate
female marmosets: Reproductive and social contributions.
Horm Behav 1998;33:58–74.
28 Kendrick KM, Dixson AF. The effect of the ovarian cycle on
the sexual behaviour of the common marmoset (Callithrix
jacchus). Physiol Behav 1983;30:735–42.
29 Kendrick KM, Dixson AF. Effects of oestradiol 17B, progest-
erone and testosterone upon proceptivity and receptivity in
ovariectomized common marmosets (Callithrix jacchus).
Physiol Behav 1985;34:123–8.
30 Allers KA, Gelez H, Sommer B, Guiliano F. Activation of the
immediate early gene c-fos by acute and repeated treatment
with ﬂibanserin. J Sex Med 2010;7(suppl 4):151.
31 Tricklebank MD, Forler C, Fozard JR. The involvement of
subtypes of the 5-HT1 receptor and of catecholaminergic
systems in the behavioural response to 8-hydroxy-2-(di-n-
propylamino)tetralin in the rat. Eur J Pharmacol 1984;106:
271–82.
32 Borsini F, Brambilla A, Cesana R, Grippa N. Lack of interac-
tion between ﬂibanserin and antidepressants in inducing sero-
tonergic syndrome in rats. Int J Neuropsychopharmacol 2001;
4:9–15.
33 Bland JM, Altman DG. Statistics notes: Transforming data.
BMJ 1996;312:770–1.
34 Guptarak J, Sarkar J, Hiegel C, Uphouse L. Role of 5-HT(1A)
receptors in ﬂuoxetine-induced lordosis inhibition. Horm
Behav 2010;58:290–6.
35 Uphouse L, Caldarola-Pastuszka M, Moore N. Inhibitory
effects of the 5-HT1A agonists, 5-hydroxy- and 5-methoxy-
(3-di-n-propylamino)chroman, on female lordosis behavior.
Neuropharmacology 1993;32:641–51.
36 Uphouse L, Caldarola-Pastuszka M. Female sexual behavior
following intracerebral infusion of the 5-HT1A agonist,
8-OH-DPAT, into the medial preoptic area. Brain Res 1993;
601:203–8.
37 Uphouse L, Maswood S, Caldarola-Pastuszka M. Agonist acti-
vation of 5-HT1A receptors in the median raphé nucleus and
female rat lordosis behavior. Brain Res 1994;668:271–5.
38 Johansson CE, Meyerson BJ, Höglund AU. The long-term
effects of 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-
DPAT) on copulatory and exploratory behaviour in male rats.
Eur J Pharmacol 1990;178:1–9.
39 Kannan S, Archunan G. Chemistry of clitoral gland secretions
of the laboratory rat: Assessment of behavioural response to
identiﬁed compounds. J Biosci 2001;26:247–52.
40 Ferris CF, Snowdon CT, King JA, Sullivan JM Jr, Ziegler TE,
Olson DP, Schultz-Darken NJ, Tannenbaum PL, Ludwig R,
Wu Z, Einspanier A, Vaughan JT, Duong TQ. Activation of
neural pathways associated with sexual arousal in non-human
primates. J Magn Reson Imaging 2004;19:168–75.
41 Ferreira-Nuño A, Morales-Otal A, Paredes RG, Velázquez-
Moctezuma J. Sexual behavior of female rats in a multiple-
partner preference test. Horm Behav 2005;47:290–6.
42 Dixson AF, Lunn SF. Post-partum changes in hormones and
sexual behaviour in captive groups of marmosets (Callithrix
jacchus). Physiol Behav 1987;41:577–83.
43 Ho SS, Chow BK, Yung WH. Serotonin increases the excit-
ability of the hypothalamic paravenricular nucleus magnocel-
lular neurons. Eur J Neurosci 2007;25:2991–3000.
44 Keverne EB, Curley JP. Vasopressin, oxytocin and social
behaviour. Curr Opin Neurobiol 2004;14:777–83.
45 de Arruda Camargo GM, de Arruda Camargo LA, Saad WA.
Role of serotonergic 5-HT1A and oxytocinergic receptors of
the lateral septal area in sodium intake regulation. Behav Brain
Res 2010;209:260–6.
46 Pedersen CA, Caldwell JD, Peterson G, Walker CH, Mason
GA. Oxytocin activation of maternal behavior in the rat. Ann
N Y Acad Sci 1992;652:58–69.
47 Bancroft J, Loftus J, Long JS. Distress about sex: A national
survey of women in heterosexual relationships. Arch Sex Behav
2003;32:193–208.
48 Carter CS. Neuroendocrine perspectives on social attachment
and love. Psychoneuroendocrinology 1998;23:779–818.
49 Snowdon CT, Ziegler TE, Schultz-Darken NJ, Ferris CF.
Social odours, sexual arousal and pairbonding in primates.
Philos Trans R Soc Lond B Biol Sci 2006;361:2079–89.
50 Evans S. The pair-bond of the common marmoset, Callithrix
jacchus jacchus: An experimental investigation. Anim Behav
1983;31:651–8.
51 Anzenberger G. How stranger encounters of common marmo-
sets (Callithrix jacchus jacchus) are inﬂuenced by family
members: The quality of behavior. Folia Primatol 1985;45:
204–24.
52 Insel TR, Winslow JT. Serotonin and neuropeptides in afﬁli-
ative behaviors. Biol Psychiatry 1998;44:207–19.
53 Young KA, Gobrogge KL, Liu Y, Wang Z. The neurobiology
of pair bonding: Insights from a socially monogamous rodent.
Front Neuroendocrinol 2011;32:53–69.
54 Ferris CF. Serotonin diminishes aggression by suppressing the
activity of the vasopressin system. Ann N Y Acad Sci 1996;794:
98–103.
55 Snowdon CT, Pieper BA, Boe CY, Cronin KA, Kurian AV,
Ziegler TE. Variation in oxytocin is related to variation in
afﬁliative behavior in monogamous, pairbonded tamarins.
Horm Behav 2010;58:614–8.
56 Gerretsen P, Graff-Guerrero A, Menon M, Pollock BG,
Kapur S, Vasdev N, Houle S, Mamo D. Is desire for social
706 Aubert et al.
J Sex Med 2012;9:694–707
relationships mediated by the serotonergic system in the pre-
frontal cortex? An [(18)F]setoperone PET study. Soc Neurosci
2010;5:375–83.
57 Allers KA, Dremencov E, Ceci A, Flik G, Ferger B, Cremers
TI, Ittrich C, Sommer B. Acute and repeated ﬂibanserin
administration in female rats modulates monoamines differen-
tially across brain areas: A microdialysis study. J Sex Med
2010;7:1757–67.
58 Ferger B, Shimasaki M, Ceci A. Flibanserin, a drug intended
for treatment of hypoactive sexual desire disorder in pre-
menopausal women, affects spontaneous motor activity and
brain neurochemistry in female rats. Naunyn Schmiedebergs
Arch Pharmacol 2010;381:573–9.
59 Arnow BA, Millheiser L, Garrett A, Lake Polan M, Glover
GH, Hill KR, Lightbody A, Watson C, Banner L, Smart T,
Buchanan T, Desmond JE. Women with hypoactive sexual
desire disorder compared to normal females: A functional
magnetic resonance imaging study. Neuroscience 2009;158:
484–502.
60 Holstege G, Willemsen A, Beers C, Lont E, Schultz WW,
Jansen M, Dierck R. Differences in brain activity in premeno-
pausal women with hyopoactive sexual desire disorder
(HSDD) compared to women without sexual dysfunction. J
Sex Med 2009;6(suppl 5):407.
61 Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the
United States: Prevalence and predictors. JAMA 1999;28:537–
44.
62 Pfaff DW. Estrogens and brain function. New York: Springer;
1980.
63 Wallen K, Zehr JL. Hormones and history: The evolution and
development of primate female sexuality. J Sex Res 2004;41:
101–12.
64 Tricklebank MD, Forler C, Middlemiss DN, Fozard JR. Sub-
types of the 5-HT receptor mediating the behavioural
responses to 5-methoxy-N,N-dimethyltryptamine in the rat.
Eur J Pharmacol 1985;117:15–24.
65 Larsson LG, Rényi L, Ross SB, Svensson B, Angeby-Möller K.
Different effects on the responses of functional pre- and
postsynaptic 5-HT1A receptors by repeated treatment of rats
with the 5-HT1A receptor agonist 8-OH-DPAT. Neurophar-
macology 1990;29:85–91.
66 Arnt J, Hyttel J. Facilitation of 8-OH-DPAT-induced forepaw
treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol
1989;161:45–51.
67 Rogóz Z, Skuza G, Legutko B. Repeated co-treatment with
ﬂuoxetine and amantadine induces brain-derived neurotrophic
factor gene expression in rats. Pharmacol Rep 2008;60:817–
26.
68 Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM.
The Hunter Serotonin Toxicity Criteria: Simple and accurate
diagnosis decision rules for serotonin toxicity. Q J Med
2003;96:635–42.
69 Isbister GK, Buckley NA. The pathophysiology of serotonin
toxicity in animals and humans: Implications for diagnosis and
treatment. Clin Neuropharmacol 2005;28:205–14.
70 Hjorth S. Hypothermia in the rat induced by the potent sero-
tonergic agent 8-OH-DPAT. J Neural Transm 1985;61:131–5.
71 Anderson IM, Cowen PJ, Grahame-Smith DG. The effects of
gepirone on neuroendocrine function and temperature in
humans. Psychopharmacology (Berl) 1990;100:498–503.
72 Brambilla A, Baschirotto A, Grippa N, Borsini F. Effect of
ﬂibanserin (BIMT 17), ﬂuoxetine, 8-OH-DPAT and bus-
pirone on serotonin synthesis in rat brain. Eur Neuropsychop-
harmacol 1999;10:63–7.
73 Bethea CL, Ku NZ, Gundlah C, Streicher JM. Diverse actions
of ovarian steroids in the serotonin neural system. Front Neu-
roendocrinol 2002;23:41–100.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1 24-hour pharmacokinetic proﬁles of 10 mg/kg and
30 mg/kg ﬂibanserin in female marmoset monkeys. Flibanserin
was administered PO at doses of 10 mg/kg or 30 mg/kg. Blood
samples were taken at 0.25 h, 0.5 h, 1 h, 3 h, 6 h and 24 h after
ﬂibanserin administration and analyzed for circulating ﬂibanserin
concentrations. Flibanserin doses did not signiﬁcantly differ
(P > 0.05; N = 4).
Table S1 In a dose-response study, the behavioral effects of
10 mg/kg or 30 mg/kg ﬂibanserin, administered to female marmo-
sets, were compared to respective baseline behavior of each indi-
vidual. Difference between ﬂibanserin doses were assessed by
three-way anova including the dose of ﬂibanserin as between-
subject factor
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